SNDX News & Events

For FY26, the company expects total research and development plus selling, general and administrative expenses to be approximately $400M, excluding the impact of $50M in estimated non-cash stock compensation expense. Syndax expects that its operating expense base will remain stable over the next couple of years. As a result, Syndax expects that its cash, cash equivalents and short-term investments, combined with its anticipated product revenue, collaboration revenue and interest income, will enable the company to reach profitability.

Reports Q4 revenue $68.73M, consensus $64.75M. As of December 31, 2025, Syndax had cash, cash equivalents, and short-term investments of $394.1M and 87.7M common shares and prefunded warrants outstanding. "We solidified our leadership position and proved the strength of Syndax's R&D and commercial capabilities in 2025, achieving our third FDA approval and successfully launching two first- and best-in-class medicines. We reached thousands of patients with Revuforj and Niktimvo and generated over $275M in 2025 sales, rapidly advancing the company towards profitability," said CEO Michael Metzger. "With strong momentum and multiple growth drivers for both products, including increasing uptake of Revuforj in R/R NPM1m AML and the post-transplant setting, Syndax is well positioned for continued growth in 2026 and beyond."